Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Publications

On This Page

Chapters, Manuals and Guidelines

Pink Book’s Chapter on Pertussis
Epidemiology & Prevention of Vaccine-Preventable Diseases textbook.
CDC. Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines. MMWR Morb Mortal Wkly Rep. 2005;54(RR14):1–16.
Travelers’ Health: Yellow Book — Chapter on Pertussis
CDC’s Health Information for International Travel 2010 (Prevention of Specific Infectious Diseases).
Surveillance Manual’s Chapter on Pertussis
Manual from the Surveillance of Vaccine-Preventable Diseases textbook.

Articles

Vaccine Recommendations and Licensures

Updated recommendations for use of tetanus toxoid, reduced diphtheria, and acellular pertussis vaccine (Tdap) in pregnant women — Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62(07):131–5.
Updated recommendation for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine in adults 65 years and older — Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2012;61(25):468–70.
Immunization of health-care personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(RR07):1–45.
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine in pregnant women and persons who have or anticipate having close contact with an infant aged less than 12 months — Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(41):1424–6.
FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2011;60(37):1279–80.
Updated recommendations for the use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep, 2011;60(01):13–15.
Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2008;57(04):1–47, 51.
Preventing tetanus, diphtheria, and pertussis among adults: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. MMWR Morb Mortal Wkly Rep. 2006;55(RR17):1–33.
Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. MMWR Morb Mortal Wkly Rep. 2006;55(RR03):1–34.
Notice to readers: FDA approval of diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, (INFANRIX®) for fifth consecutive DTaP vaccine dose. MMWR Morb Mortal Wkly Rep. 2003;52(38):921.
Notice to readers: FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (Recombinant), and poliovirus vaccine combined, (PEDIARIX™) for use in infants. MMWR Morb Mortal Wkly Rep. 2003;52(10):203–204.
Notice to readers: Food and Drug Administration approval of a fifth acellular pertussis vaccine for use among infants and young children — United States, 2002.MMWR Morb Mortal Wkly Rep. 2002;51(26):574.
Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. MMWR Morb Mortal Wkly Rep. 2000;49(RR13):1–8.
Combination vaccines for childhood immunization. MMWR Morb Mortal Wkly Rep. 1999;48(RR05):1–15.
Notice to readers FDA approval of a fourth acellular pertussis vaccine for use among infants and young children. MMWR Morb Mortal Wkly Rep. 1998;47(43):934–6.
Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(RR-7):1–25.
Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and other preventive measures Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991;40(RR10):1–28.

Surveillance, Epidemiology and Outbreaks

McNamara LA, Skoff T, Faulkner A, et al. Reduced severity of pertussis in person with age-appropriate pertussis vaccination — United States, 2010–2012. Clin Infect Dis. Epub ahead of print. 2017.
Blain A, Lewis M, Banerjee E, et al. An assessment of the cocooning strategy for preventing infant pertussis — United States, 2011. Clin Infect Dis. 2016; 63(4):S221–6.
Curtis CR, Baughman AL, Debolt C, et al. Risk factors associated with Bordetella pertussis among infants aged ≤4 months in the pre-Tdap era — United States, 2002-2005. Pediatr Infect Dis J. 2016. [Epub ahead of print].
Terranella A, Rea V, Griffith M, et al. Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine. Vaccine. 2016;34(22):2496–500.
O’Halloran A, Lu P, Williams WW, Ding H, Meyer S. Tetanus, diphtheria, and acellular pertussis vaccination among women of childbearing age — United States, 2013. Am J Infect Contr. 2016;44(7):786–93.
Breakwell L, Kelso P, Finley C, et al. Pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis. Pediatrics. 2016;137(5):e20153973.
Matthias J, Pritchard PS, Martin SW, et al. Sustained transmission of pertussis in a highly vaccinated preschool: A 1-5-year-old cohort. Emerg Infect Dis. 2016;22(2):242–6.
Skoff TH, Martin SW. Impact of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccinations on reported pertussis cases among those 11 to 18 years of age in an era of waning pertussis immunity: A follow-up analysis. JAMA Pediatrics. 2016;170(5):453–8.
Skoff TH, Kenyon C, Cocoros N, et al. Source of infant pertussis infection in the United States. Pediatrics. 2015;136(4):635–41.
Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington state pertussis epidemic. Pediatrics. 2015;135:981–9.
Tiwari TS, Baughman AL, Clark TA. First pertussis vaccine dose and prevention of infant mortality. Pediatrics. 2015;135:990–9.
Gambhir M, Clark TA, Cauchemez S, Tartof SY, Swerdlow DL, Ferguson NM. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. PLoS Comput Biol. 2015;11(4):e1004138.
Hewlett EL, Burns DL, Cotter PA, et al. Pertussis pathogenesis—what we know and what we don’t know. J Infect Dis. 2014;209(7):982–5.
Lu PJ, Graitcer SB, O’Halloran A, Liang JL. Tetanus, diphtheria and acellular pertussis (Tdap) vaccination among healthcare personnel—United States, 2011. Vaccine. 2014;32(5):572–8.
Matthias J, Dusek C, Pritchard PS, Rutledge L, Kinchen P, Lander M. Notes from the field: Outbreak of pertussis in a school and religious community averse to health care and vaccinations — Columbia County, Florida, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(30):655.
Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis — Ohio, 2010-2011. Clin Infect Dis. 2013;56:322–31.
Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131:e1047–52.
Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308:2126–32.
CDC. Pertussis Epidemic — Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61(28):517-22.
Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new? Trends Microbiol. 2012;20:211–3.
Mandal S, Tatti KM, Woods-Stout D, et al. Pertussis pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA from clinic surfaces. Pediatrics. 2012;129:e424–30.
Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW. Early impact of the US Tdap vaccination program on pertussis trends. Arch Pediatr Adolesc Med. 2012;166:344–9.
Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine. 2010;28:8001–7.
CDC. Tetanus and pertussis vaccination coverage among adults aged ≥18 years — United States, 1999 and 2008. MMWR Morb Mortal Wkly Rep. 2010;59(40):1302–6.
Wei S, Tatti K, Cushing K, Rosen J, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine (Tdap) against pertussis. Clin Infect Dis. 2010;51:315–21.
CDC. Use of mass Tdap vaccination to control an outbreak of pertussis in a high school–Cook County, Illinois, September 2006-January 2007. MMWR Morb Mortal Wkly Rep. 2008;57(29):796–9.
CDC. Hospital-acquired pertussis among newborns — Texas, 2004. MMWR. 2008;57(22):600–3.
Cassiday P, Tobin-D’Angelo M, Watson J, Wu KH, Park M, Sanden G. Co-infection with two different strains of Bordetella pertussis in an infant. J Med Microbiol. 2008;57:388.
CDC. Outbreaks of Respiratory Illness Mistakenly Attributed to Pertussis — New Hampshire, Massachusetts, and Tennessee, 2004–2006. MMWR Morb Mortal Wkly Rep. 2007; 56(33):837–842.
CDC. Pertussis outbreak in an Amish community — Kent County, Delaware, September 2004–February 2005. MMWR Morb Mortal Wkly Rep. 2006;55(30):817–21.
CDC. Pertussis — United States, 2001-2003. MMWR Morb Mortal Wkly Rep. 2005;54(50):1283–86.
CDC. Outbreaks of pertussis associated with hospitals — Kentucky, Pennsylvania, and Oregon, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(3):67–71.
CDC. School-associated pertussis outbreak-Yavapai County, Arizona, September 2002-February 2003. MMWR Morb Mortal Wkly Rep. 2004;53(10):216–9.
CDC. Fatal case of unsuspected pertussis diagnosed from a blood culture — Minnesota, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(6):131–2.
CDC. Pertussis outbreak among adults at an oil refinery — Illinois, August–October 2002. MMWR Morb Mortal Wkly Rep. 2003;52(01):1–4.
Brennan M, Strebel P, George H, et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: Epidemiologic data supported by pulsed-field gel electrophoresis studies. J Infect Dis. 1999;181:210–5
CDC. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending December 19, 1998 and December 13, 1997 (50th Week). MMWR Morb Mortal Wkly Rep. 1998;47(50):1101–6.
CDC. Case Definitions for Infectious Conditions Under Public Health Surveillance. MMWR Morb Mortal Wkly Rep. 1997;46(RR10):1–55.

Laboratory

Weigand MR, Peng Y, Loparev V, et al. The history of Bordetella pertussis genome evolution includes structural rearrangement. J Bacteriol. 2017;199(8): e00806-16.
Gates I, DuVall M, Ju Hong, Tondella ML, Pertussis Working Group, Pawloski L. Development of a qualitative assay for screening of Bordetella pertussis isolates for pertussis toxin production. PloS One. 2017;12(4):e0175326.
Weigand MR, Peng Y, Loparev V, et al. Complete genome sequences of four Bordetella pertussis vaccine reference strains from Serum Institute of India. Genome Announc. 2016 4(6): e01404-16.
Weigand MR, Peng Y, Loparev V, et al. Complete genome sequences of Bordetella pertussis vaccine reference strains 134 and 10536. Genome Announce. 2016;4(5):e00979–16.
Pawloski L, Plikaytis B, Martin M, et al. Evaluation of commercial assays for single-point diagnosis of pertussis in the US. J Ped Infect Dis Soc. 2016 Jul 22. [Epub ahead of print]
Bowden KE, Weigand MR, Peng Y, et al. Genome structural diversity among 31 Bordetella pertussis isolates from two recent US whooping cough statewide epidemics. mSphere. 2016;1(3)e00036–16.
Cassiday PK, Skoff TH, Jawahir S, Tondella ML. Changes in predominance of pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates, United States, 2000–2012. Emerg Infect Dis. 2016;22(3):442–8.
Faulkner A, Skoff TH, Tondella L, Cohn A, Clark TA, Martin SW. Trends in pertussis diagnostic testing in the United States, 1990-2012. Pediatr Infect Dis J. 2016;35(1):39–44.
Williams MM, Sen K, Weigand MR, et al. Bordetella pertussis lacking pertactin and pertussis toxin: Report of a clinical case. Emerg Infect Dis. 2016;22(2):319–22.
Williams MM, Taylor TH Jr, Warshauer DM, Martin MD, Valley AM, Tondella ML. Harmonization of Bordetella pertussis real-time PCR diagnostics in the US, 2012. J Clin Microbiol. 2015;53(1):118–23.
Martin SW, Pawloski L, Williams M, et al. Pertactin-negative B. pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60(2):223–7.
Bowden KE, Williams MM, Cassiday PK, et al. Molecular epidemiology of pertussis epidemic — Washington State, 2012. J Clin Microbiol. 2014;52(10):3549–57.
Vaz-de-Lima LR, Martin MD, Pawloski LC, et al. Serodiagnosis as adjunct assay for pertussis infection in Sao Paulo, Brazil. Clin Vaccine Immunol. 2014;21(5):636–40.
Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio. 2014;5:e01074.
Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol. 2014;21:119–25.
Harvill ET, Goodfield LL, Ivanov Y, et al. Genome sequences of 28 Bordetella pertussis U.S. outbreak strains dating from 2010 to 2012. Genome Announc. 2013;1:e01075–13.
Tatti KM, Martin SW, Boney KO, Brown K, Clark TA, Tondella ML. Qualitative assessment of pertussis diagnostics in United States laboratories. Pediatr Infect Dis J. 2013;32:942–5.
Tatti KM, Loparev VN, Ranganathanganakammal S, et al. Draft genome sequences of Bordetella holmesii strains from blood (F627) and nasopharynx (H558). Genome Announc. 2013;1:e0005613.
Tatti KM, Tondella ML. Utilization of multiple real-time PCR assays for the diagnosis of Bordetella spp. in clinical specimens. Methods Mol Biol. 2013;943:135–47.
Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Eng J Med. 2013;368:583–4.
Rodgers L, Martin SW, Cohn A, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis–Ohio, 2010-2011. Clin Infect Dis. 2013;56:322–31.
Bottero D, Griffith MM, Lara C, et al. Bordetella holmesii in children suspected of pertussis in Argentina. Epidemiol Infect. 2013;141:714–7.
Schmidtke AJ, Boney KO, Martin SW, Skoff TH, Tondella ML, Tatti KM. Population diversity among Bordetella pertussis isolates, United States, 1935–2009. Emerg Infect Dis. 2012;18:1248–55.
Pawloski LC, Kirkland KB, Baughman AL, et al. Does Tdap vaccination interfere with serodiagnosis of pertussis infection? Clin Vaccine Immunol. 2012;19:975–80.
Mandal S, Tatti KM, Woods-Stout D, et al. Pertussis pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA from clinic surfaces. Pediatrics. 2012;129:e424–30.
Kapasi A, Meade BD, Plikaytis B, et al. Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG Anti-PT ELISAs. Clin Vaccine Immunol. 2012;19:64–72.
Tatti KM, Sparks KN, Boney KO, Tondella ML Novel multi-target real-time PCR assay for the rapid diagnosis of Bordetella species in clinical specimens. J Clin Microbiol. 2011;49:4059–66.
Bolt F, Cassiday P, Tondella ML, et al. Multilocus sequence typing identifies evidence for recombination and two distinct lineages of Corynebacterium diphtheriae. J Clin Microbiol. 2010;48:4177–85.
Hall AJ, Cassiday PK, Bernard KA, et al. Novel Corynebacterium diphtheriae in domestic cats. Emerg Infect Dis. 2010;16:688–91.
Menzies SL, Kadwad V, Pawloski LC, et al. Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection. Clin Vaccine Immunol. 2009;16:1781–88.
Tondella ML, Carlone G, Messonnier N, et al. International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007. Vaccine. 2009;27:803–14.
Tatti K, Wu KH, Tondella ML, et al. Development and evaluation of dual-target real-time polymerase chain reaction assays to detect Bordetella spp. Diagn Micr Infec Dis. 2008;61:264–72.
Tatti K, Slade B, Patel M, et al. Real-time polymerase chain reaction detection of Bordetella pertussis DNA in acellular pertussis vaccines. Pediatr Infect Dis J. 2008;27):73–4.
Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis. 2008;47:328–38.
Tatti K, Wu KH, Sanden G, et al. Molecular diagnosis of Bordetella pertussis infection by evaluation of formalin-fixed tissue specimens. J Clin Microbiol. 2006;44(3):1074–6.
CDC. Fatal case of unsuspected pertussis diagnosed from a blood culture–Minnesota, 2003(https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5306a5.htm) MMWR. 2004;53(6):131–2.
Hardwick T, Cassiday P, Weyant R, Bisgard K, Sanden G. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999(https://www.cdc.gov/ncidod/EID/vol8no1/01-0021.htm). Emerg Infect Dis. 2002;8:44–9.
Hardwick T, Plikaytis B, Cassiday P, et al. Reproducibility of Bordetella pertussis genomic DNA fragments generated by Xba I restriction and resolved by pulsed-field gel electrophoresis. J Clin Microbiol. 2002;40:811–6.
Bisgard K, Christie C, Reising S, et al. Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. J Infect Dis. 2001;183:1360–7.
Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard K, Popovic T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis. 2000;182:1402–8.
Kurzynski TA, Boehm DM, Rott-Petri J, Schell R, Allison P. Comparison of modified Bordet-Gengou and modified Regan-Lowe media for the isolation of Bordetella pertussis and Bordetella parapertussis. J Clin Microbiol. 1998;26:2661–3.
Brennan M, Strebel P, George H, et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis studies. J Infect Dis. 1999;181:210–5.
Beall B, Cassiday P, Sanden G. Analysis of Bordetella pertussis isolates from an epidemic by pulsed-field gel electrophoresis. J Clin Microbiol. 1995;33:3083–6.
Ruijs GJ, Groenendijk TW, Biever M. Shelf life of prepared Bordet-Gengou and Regan-Lowe agar plates for isolation of Bordetella pertussis. Eur J Clin Microbiol Infect Dis. 1991;10:974–8.
Regan J, Lowe F. Enrichment medium for the isolation of Bordetella. J Clin Microbiol. 1977;6:303–9.

File Formats Help:

How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?

Page last reviewed: August 7, 2017
Page last updated: August 7, 2017
Content source:
- National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases

TOP